找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Current Management of Melanoma; Ferdinando Cafiero,Franco De Cian Book 2021 Springer Nature Switzerland AG 2021 surgery treatment.sentinel

[復(fù)制鏈接]
樓主: fungus
41#
發(fā)表于 2025-3-28 17:50:21 | 只看該作者
Slips of Paper and Performance Artrocedure. Lymph node involvement is diagnosed in different ways, most frequently after sentinel lymph node biopsy (SLNB), but some patients may present clinical evident metastases at diagnosis or during the follow-up. In the case of positive SLNB, about 15–20% of patients have additional metastatic
42#
發(fā)表于 2025-3-28 21:50:28 | 只看該作者
https://doi.org/10.1007/978-3-319-45772-7mphocele, hematomas and lymphedema. Secondary lymphedema of the limbs is a debilitating and progressive condition that commonly occurs following melanoma treatment. The technique known as lymphatic microsurgical preventive healing approach (LYMPHA) is able to prevent secondary lymphedema following l
43#
發(fā)表于 2025-3-28 23:08:57 | 只看該作者
44#
發(fā)表于 2025-3-29 06:25:50 | 只看該作者
Zheng Liu,Shuting Guo,Tao Li,Wenyan Chen increase in surgical indications also for patients with metastatic melanoma. The surgical indications in this disease setting can be summarized as: collection of biological material; treatment of oligometastatic disease; treatment beyond progression; palliation surgery. In selected cases, surgical
45#
發(fā)表于 2025-3-29 10:59:38 | 只看該作者
Peizhong Yang,Lihua Zhou,Hongmei Chenith resected, high-risk melanoma. After a 20-year era of adjuvant interferon, checkpoint inhibitor immunotherapy and BRAF+MEK inhibitors revolutionized the management of melanoma in everyday clinical practice. In this review, we summarize the current state of the art of the adjuvant treatment of hig
46#
發(fā)表于 2025-3-29 13:09:00 | 只看該作者
47#
發(fā)表于 2025-3-29 16:06:48 | 只看該作者
48#
發(fā)表于 2025-3-29 22:43:09 | 只看該作者
49#
發(fā)表于 2025-3-30 02:03:36 | 只看該作者
Updates in Surgeryhttp://image.papertrans.cn/d/image/241238.jpg
50#
發(fā)表于 2025-3-30 06:09:33 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-21 15:29
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
平谷区| 蒲江县| 天祝| 博白县| 察隅县| 洪江市| 延津县| 岳西县| 射洪县| 全椒县| 临沧市| 原平市| 高平市| 宣威市| 凤台县| 宾阳县| 根河市| 仁寿县| 饶河县| 阳春市| 祁连县| 苏尼特右旗| 纳雍县| 吉木乃县| 双峰县| 靖西县| 册亨县| 凤山县| 石嘴山市| 滨海县| 蒙阴县| 关岭| 东丰县| 嫩江县| 临泉县| 临澧县| 四会市| 潮安县| 上栗县| 三明市| 临汾市|